No Data
Beijing Tiantan Biological Products Corporation (600161.SH): The clinical trial summary report of recombinant human coagulation Indicators VIIa for injection has shown good efficacy.
Beijing Tiantan Biological Products Corporation (600161.SH) announced that its subsidiary Chengdu Rongsing Pharmaceutical Co., Ltd. (abbreviated as "Cheng...")
Beijing Tiantan Biological Products Corporation (600161.SH): signed a leasing contract with a related party.
On December 30, Ge Longhui reported that Beijing Tiantan Biological Products Corporation (600161.SH) announced that the company owns the land use rights and the ownership of its above-ground attachments at No. 2, B District, Shuangqiao Road, Chaoyang District, Peking. The company has signed a lease agreement with the related party Beijing China National Pharmaceutical Asset Management Co., Ltd. (hereinafter referred to as "National Pharmaceutical Asset Company"), leasing part of the assets of the park (actual building area of 18,676.80 square meters) to National Pharmaceutical Asset Company. The aforementioned lease agreement will expire on December 31, 2024.
Beijing Tiantan Biological Products Corporation (600161.SH): Clinical trial of intravenous COVID-19 human immunoglobulin (pH4) terminated.
Beijing Tiantan Biological Products Corporation (600161.SH) announced that its subsidiary, Sinopharm Group Wuhan Biological Products Co., Ltd., has developed...
Beijing Tiantan Biological Products Corporation (600161.SH): Subsidiary company's Pharmaceutical clinical trials have been terminated.
Gelonghui, December 27丨Beijing Tiantan Biological Products Corporation (600161.SH) announced that its subsidiary, China National Pharmaceutical Group Wuhan Biological Products Co., Ltd., has developed the "Intravenous COVID-19 Human Immunoglobulin (pH 4)" which is currently in the Phase II clinical trial research stage. Recently, after comprehensive assessment, the company has decided to terminate the Phase II clinical trial research and subsequent development of this drug.
Beijing Tiantan Biological Products Corporation (600161.SH): The affiliated enterprise "subcutaneous injection of human immunoglobulin" has completed phase III clinical trials and obtained the clinical trial summary report.
On November 22, Gelonghui reported that beijing tiantan biological products corporation (600161.SH) announced that its subsidiary, Chengdu Rongsheng Pharmaceutical Co., Ltd. (referred to as 'Chengdu Rongsheng'), has completed the phase III clinical trial of 'subcutaneous human immunoglobulin' and obtained the clinical trial summary report. The clinical research results of the subcutaneous human immunoglobulin produced by Chengdu Rongsheng show that after administration, it can maintain a more stable serum concentration of immunoglobulin G (igg) and effectively reduce the occurrence of serious bacterial infections (SBI), demonstrating good efficacy and safety for patients with primary immunodeficiency diseases (PID).
Beijing Tiantan Biological Products Corporation (600161.SH): The "Human Prothrombin Complex" developed has completed clinical ethical review, pre-clinical preparation for inclusion and other work, and officially started phase III clinical trials recently.
Gelonghui October 31st news | beijing tiantan biological products corporation (600161.SH) announced that the "Human Prothrombin Complex" developed by its subsidiary guizhou biological pharmaceutical co., ltd. of China National Pharmaceutical Group has completed the clinical ethical review, pre-clinical recruitment preparation, and officially launched phase III clinical trials in recent days.
